BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo on Monday, May 14, 2007 at 11:30 a.m. CET (5:30 a.m. ET).

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease.

  Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc.

  Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

CONTACTS: investors, Eugenia Shen, +1-415-506-6570, or media, Susan Berg, +1-415-506-6594, both of BioMarin Pharmaceutical Inc.

FCMN Contact: eshen@bmrn.com

SOURCE: BioMarin Pharmaceutical Inc.